Imbruvica is an important drug for AbbVie and is its biggest revenue producer ... because they have historically responded poorly to ibrutinib therapy. Despite the failure to meet the overall ...

with AbbVie's share dipping in trading after the announcement. Launched in 2013, Imbruvica (ibrutinib) earned $548 million last year, with $492 million of that in the US where Pharmacyclics ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185. Despite strong dividends and share buybacks, AbbVie’s higher P/E ratio ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...